By integrating structural, mechanistic, and pharmacological insights, this review aims to pave the way for the rational design of next-generation MetAP2 inhibitors, offering new hope for effective and safe treatments for obesity and T2DM. The gene discussed is METAP2; the disease is type 2 diabetes mellitus.